Dave Muoio

The FDA has granted Isreal-based DreaMed Diabetes a de novo request for its artificial intelligence-powered software for providers managing patients with Type 1 diabetes.

Biometric sensor technology company Valencell announced this week that it has raised $10.

DyAnsys, a medical device company specializing in the autonomic nervous system, announced this week that it has received FDA approval for a wearable auricular neurostimulation device designed to treat symptoms of opioid withdrawal.

The past month has seen a succession of publications offering support for Click Therapeutics’ digital offering for patients with major depressive disorder (MDD).

SleepScore Labs — a joint venture between ResMed, Dr.

Stockholm, Sweden-based telemedicine app company Kry announced this week that it has raised $66 million (53 million euros) in Series B funding.

When healthcare communications firm Spok first began investigating the prevalence of mobile strategies in 2012, only a third of survey respondents reported that their organization had a formalized strategy in place.

Switzerland-based MindMaze announced today that it has received FDA clearance for the MindMotion Go, a gamified neurorehabilitation therapy platform for medium and light severity impairments able to be deployed in the patient’s home.

Medidata, a New York City-based company that offers cloud storage and data analytics services for clinical trials, announced today that it has acquired Shyft Analytics, maker of a cloud data analytics platform specifically designed for the pharma and biotech industries.

Digital technologies are cementing their place across healthcare, and the pharmaceutical sector is no exception.